Login Register Cart 0
Generic placeholder image

Current Rheumatology Reviews

Editor-in-Chief

ISSN (Print): 1573-3971
ISSN (Online): 1875-6360

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Psoriatic Arthritis Experience in Saudi Arabia from the Rheumatologist and Patient Perspectives

Author(s): Ibrahim Alhomood*, Mohamed Fatani, Mohamed Bedaiwi, Sahar Al Natour, Alper Erdogan, Aya Alsharafi and Suzan Attar

Volume 19, Issue 4, 2023

Published on: 08 June, 2023

Page: [470 - 478] Pages: 9

DOI: 10.2174/1573397119666230516162221

Price: $65

Abstract

Background: Psoriatic arthritis (PsA) is a musculoskeletal disease that adversely affects physical mobility and quality of life. It is challenging to manage because of the heterogeneous nature of the symptoms and the current treatment options.

Purpose: To explore the patient and rheumatologist perspectives of PsA to help improve understanding of the disease experience and improve disease management.

Methods: A descriptive, observational cross-sectional study of Saudi Arabian dermatologists and rheumatologists and patients with psoriasis or PsA was conducted. Questionnaire data were collected from 31 dermatologists, 34 rheumatologists, 90 patients with psoriasis, and 98 patients with PsA and analysed using descriptive statistics. Here, data from rheumatologists and patients with PsA are presented.

Results: The results revealed similarities and differences in the rheumatologist and patient perspectives of PsA. Rheumatologists and patients agreed on the impact that PsA had on patients’ quality of life and that more education was needed. However, they differed on several aspects of disease management. Rheumatologists estimated the time to diagnosis as four times shorter than what patients experienced. Patients accepted their diagnosis more than rheumatologists perceived them to; rheumatologists perceived patients to be worried or fearful. Patients perceived joint pain as their most severe symptom, in contrast to rheumatologists, who presumed skin appearance was the most severe symptom. Reported input into PsA treatment goals differed significantly. More than half of the rheumatologists reported equal patient-physician input into goal development as opposed to <10% of patients reporting the same. Almost half of patients reported no input into the development of their treatment goals.

Conclusion: The management of PsA could benefit from enhanced screening and re-evaluation of what PsA outcomes have the most value to patients and rheumatologists. A multidisciplinary approach is recommended with increased patient involvement in disease management and individualized treatment options.

« Previous Next »
[1]
Verhoeven F, Prati C, Demougeot C, Wendling D. Cardiovascular risk in psoriatic arthritis, a narrative review. Joint Bone Spine 2020; 87(5): 413-8.
[http://dx.doi.org/10.1016/j.jbspin.2019.12.004] [PMID: 31958573]
[2]
Umezawa Y. Psoriatic arthritis. J Dermatol 2021; 48(6): 741-9.
[http://dx.doi.org/10.1111/1346-8138.15954] [PMID: 34060132]
[3]
Stober C. Pathogenesis of psoriatic arthritis. Best Pract Res Clin Rheumatol 2021; 35(2): 101694.
[http://dx.doi.org/10.1016/j.berh.2021.101694] [PMID: 34108102]
[4]
Villani AP, Rouzaud M, Sevrain M, et al. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. J Am Acad Dermatol 2015; 73(2): 242-8.
[http://dx.doi.org/10.1016/j.jaad.2015.05.001] [PMID: 26054432]
[5]
Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. J Dermatolog Treat 2020; 31(7): 662-79.
[http://dx.doi.org/10.1080/09546634.2019.1605142] [PMID: 31014154]
[6]
Batko B. Patient-centered care in psoriatic arthritis-a perspective on inflammation, disease activity, and psychosocial factors. J Clin Med 2020; 9(10): 3103.
[http://dx.doi.org/10.3390/jcm9103103] [PMID: 32992983]
[7]
Ogdie A, Michaud K, Nowak M, et al. Patient’s experience of psoriatic arthritis: A conceptual model based on qualitative interviews. RMD Open 2020; 6(3): e001321.
[http://dx.doi.org/10.1136/rmdopen-2020-001321] [PMID: 33115768]
[8]
Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: Outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006; 54(4): 685-704.
[http://dx.doi.org/10.1016/j.jaad.2005.10.008] [PMID: 16546593]
[9]
Mease P, Strand V, Gladman D. Functional impairment measurement in psoriatic arthritis: Importance and challenges. Semin Arthritis Rheum 2018; 48(3): 436-48.
[http://dx.doi.org/10.1016/j.semarthrit.2018.05.010] [PMID: 30029795]
[10]
Sunkureddi P, Doogan S, Heid J, et al. Evaluation of self-reported patient experiences: Insights from digital patient communities in psoriatic arthritis. J Rheumatol 2018; 45(5): 638-47.
[http://dx.doi.org/10.3899/jrheum.170500] [PMID: 29449495]
[11]
Gorter S, van der Heijde DM, van der Linden S, et al. Psoriatic arthritis: Performance of rheumatologists in daily practice. Ann Rheum Dis 2002; 61(3): 219-24.
[http://dx.doi.org/10.1136/ard.61.3.219] [PMID: 11830426]
[12]
Su YJ. Early diagnosis of psoriatic arthritis among psoriasis patients: Clinical experience sharing. Clin Rheumatol 2020; 39(12): 3677-84.
[http://dx.doi.org/10.1007/s10067-020-05132-1] [PMID: 32468320]
[13]
Belinchón I, Salgado-Boquete L, López-Ferrer A, et al. Dermatologists’ role in the early diagnosis of psoriatic arthritis: Expert recommendations. Actas Dermosifiliogr 2020; 111(10): 835-46.
[http://dx.doi.org/10.1016/j.adengl.2020.10.025] [PMID: 32659259]
[14]
Aydin SZ, Mathew AJ, Koppikar S, Eder L, Østergaard M. Imaging in the diagnosis and management of peripheral psoriatic arthritis. Best Pract Res Clin Rheumatol 2020; 34(6): 101594.
[http://dx.doi.org/10.1016/j.berh.2020.101594] [PMID: 33032929]
[15]
Bedaiwi M, Al-Homood IA, El-Garf A, et al. Disease burden and treatment challenges of psoriatic arthritis in Africa and the Middle East. Rheumatol Int 2019; 39(8): 1321-9.
[http://dx.doi.org/10.1007/s00296-019-04319-3] [PMID: 31134289]
[16]
Talotta R, Atzeni F, Sarzi-Puttini P, Masala IF. Psoriatic arthritis: From pathogenesis to pharmacologic management. Pharmacol Res 2019; 148: 104394.
[http://dx.doi.org/10.1016/j.phrs.2019.104394] [PMID: 31505253]
[17]
Miyagawa I, Tanaka Y. The approach to precision medicine for the treatment of psoriatic arthritis. Immunol Med 2020; 43(3): 98-102.
[http://dx.doi.org/10.1080/25785826.2020.1753430] [PMID: 32306849]
[18]
Köhm M, Behrens F. Treatment of psoriatic arthritis: Are there differential indications? Z Rheumatol 2020; 79(1): 23-32.
[PMID: 31578612]
[19]
Kavanaugh A, Gladman DD, Edwards CJ, et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. Arthritis Res Ther 2019; 21(1): 118.
[http://dx.doi.org/10.1186/s13075-019-1901-3] [PMID: 31077258]
[20]
Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis: A population-based study. J Rheumatol 2021; 48(9): 1410-6.
[http://dx.doi.org/10.3899/jrheum.201199] [PMID: 33589556]
[21]
Sørensen J, Hetland ML. Diagnostic delay in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: Results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2015; 74(3): e12.
[http://dx.doi.org/10.1136/annrheumdis-2013-204867] [PMID: 24534758]
[22]
Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: Results from the population-based multinational assessment of psoriasis and psoriatic arthritis survey. J Am Acad Dermatol 2014; 70(5): 871-881.e30, 30.
[http://dx.doi.org/10.1016/j.jaad.2013.12.018] [PMID: 24576585]
[23]
Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: Patient perspectives from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. Rheumatol Ther 2016; 3(1): 91-102.
[http://dx.doi.org/10.1007/s40744-016-0029-z] [PMID: 27747516]
[24]
Dures E, Bowen C, Brooke M, et al. Diagnosis and initial management in psoriatic arthritis: A qualitative study with patients. Rheumatol Adv Pract 2019; 3(2): rkz022.
[http://dx.doi.org/10.1093/rap/rkz022] [PMID: 31528844]
[25]
Carter K, Walmsley S, Rome K, Turner DE. Health professional views on the assessment and management of foot problems in people with psoriatic arthritis in Australia and New Zealand: A qualitative investigation. BMC Musculoskelet Disord 2019; 20(1): 191.
[http://dx.doi.org/10.1186/s12891-019-2572-6] [PMID: 31054575]
[26]
Silverthorne C, Lord J, Bowen D, et al. Experiences of screening and diagnosis from the perspective of patients with psoriasis and psoriatic arthritis (PSA). Ann Rheum Dis 2021; 80 (Suppl. 1): 1426.
[http://dx.doi.org/10.1136/annrheumdis-2021-eular.1024]
[27]
Perez-Chada LM, Gottlieb AB, Cohen J, et al. Measuring psoriatic arthritis symptoms: A core domain in psoriasis clinical trials. J Am Acad Dermatol 2020; 82(1): 54-61.
[http://dx.doi.org/10.1016/j.jaad.2019.05.075] [PMID: 31163240]
[28]
Howells L, Chisholm A, Cotterill S, Chinoy H, Warren RB, Bundy C. Impact of disease severity, illness beliefs, and coping strategies on outcomes in psoriatic arthritis. Arthritis Care Res 2018; 70(2): 295-302.
[http://dx.doi.org/10.1002/acr.23330] [PMID: 28771988]
[29]
Goel N. Conducting research in psoriatic arthritis: The emerging role of patient research partners. Rheumatology 2020; 59 (Suppl. 1): i47-55.
[http://dx.doi.org/10.1093/rheumatology/kez338] [PMID: 32159791]
[30]
Nowell WB, Gavigan K, Kannowski CL, et al. Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in Arthritis Power. Arthritis Res Ther 2021; 23(1): 53.
[http://dx.doi.org/10.1186/s13075-021-02430-0] [PMID: 33568191]
[31]
Furst DE, Tran M, Sullivan E, et al. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol 2017; 36(9): 2045-54.
[http://dx.doi.org/10.1007/s10067-017-3578-9] [PMID: 28238086]
[32]
Ruderman EM. Current perspectives in the recognition and management of psoriatic arthritis: implications for integrated patient care. Am J Manag Care 2002; 8 (Suppl. 6): S171-80.
[PMID: 11990862]
[33]
Barton JL, Imboden J, Graf J, Glidden D, Yelin EH, Schillinger D. Patient-physician discordance in assessments of global disease severity in rheumatoid arthritis. Arthritis Care Res 2010; 62(6): 857-64.
[http://dx.doi.org/10.1002/acr.20132] [PMID: 20535797]
[34]
Nicolau G, Yogui MM, Vallochi TL, Gianini RJ, Laurindo IM, Novaes GS. Sources of discrepancy in patient and physician global assessments of rheumatoid arthritis disease activity. J Rheumatol 2004; 31(7): 1293-6.
[PMID: 15229946]
[35]
Betteridge N, Boehncke WH, Bundy C, Gossec L, Gratacós J, Augustin M. Promoting patient‐centred care in psoriatic arthritis: A multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol 2016; 30(4): 576-85.
[http://dx.doi.org/10.1111/jdv.13306] [PMID: 26377041]
[36]
Afifi L, Shankle L, Armstrong AW, et al. National Psoriasis Foundation priorities for patient-centered research: Proceedings from the 2016 conference. J Psoriasis Psoriatic Arthritis 2017; 2(3): 73-80.
[http://dx.doi.org/10.1177/247553031700200307] [PMID: 28825055]
[37]
Dures E, Shepperd S, Mukherjee S, et al. Treat-to-target in PsA: Methods and necessity. RMD Open 2020; 6(1): e001083.
[http://dx.doi.org/10.1136/rmdopen-2019-001083] [PMID: 32071281]
[38]
Coates LC, Bushmakin AG, FitzGerald O, et al. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. Arthritis Res Ther 2021; 23(1): 94.
[http://dx.doi.org/10.1186/s13075-021-02474-2] [PMID: 33766074]
[39]
Tahir H, Grewal S. Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis. Expert Opin Pharmacother 2022; 23(4): 417-20.
[http://dx.doi.org/10.1080/14656566.2021.2006184] [PMID: 34787511]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy